← Patent-cliff monitor small molecule LORBRENA LORLATINIB
Loss of exclusivity October 2038 latest FDA-listed patent expiry
Company Pfizer → See this company's full patent-cliff portfolio Drug detail Brand name LORBRENA Active ingredient LORLATINIB Strength 25MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval November 2018 Marketing status RX
Listed patents Patent Expires Type 11299500 October 2038 substance 10420749 July 2036 substance, product 11020376 July 2036 product 8680111 March 2033 substance, product
Regulatory exclusivity Code Expires ODE-349 March 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.